Skip to main content
logo
Aurobindo Pharma Limited (NSE:AUROPHARMA)
India flag India · Delayed Price · Currency is INR
1,580.00
+3.70 (0.23%)
Jul 31, 2026, 3:30 PM IST

Aurobindo Pharma Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
35,04834,85931,73019,27526,482
Depreciation & Amortization
17,78215,21214,39411,96210,833
Other Amortization
-699.6525.2413.1432.4
Loss (Gain) From Sale of Assets
24389.4-234.9-132.31,558
Asset Writedown & Restructuring Costs
317.6696.4623.7309.9-396.3
Loss (Gain) From Sale of Investments
-14.2-367-1--264.3
Loss (Gain) on Equity Investments
-15.2316.9171.5116.7312.5
Provision & Write-off of Bad Debts
132.6188232.8524.5-61.1
Other Operating Activities
131.2-3.5-6,3452,348-4,309
Change in Accounts Receivable
-11,707-8,621-2,642-4,321-4,108
Change in Inventory
-14,998-7,355-13,037-9,26714,975
Change in Accounts Payable
12,816-3,1095,8287,0771,107
Change in Other Net Operating Assets
15,5296,640-6,900-4,4383,605
Operating Cash Flow
55,26439,24624,34523,86850,165
Operating Cash Flow Growth
40.81%61.21%2.00%-52.42%50.69%

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-26,858-19,679-27,803-24,038-20,529
Sale of Property, Plant & Equipment
462.528.4602.8110.93,809
Cash Acquisitions
-3,032-113.9--1,970-5,814
Divestitures
----43.2
Sale (Purchase) of Intangibles
-4,189-5,517-7,812-3,166-6,517
Investment in Securities
-7,819881.61,5354,428-3,361
Other Investing Activities
6,8495,641-9,082-15,142252.6
Investing Cash Flow
-34,586-18,758-42,560-39,778-32,116

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
3,59220,611-20,697-
Long-Term Debt Issued
3,6076,61415,6323,936827.3
Total Debt Issued
7,19927,22615,63224,633827.3
Short-Term Debt Repaid
---847.6--26,367
Long-Term Debt Repaid
-14,125-12,287-1,638-981.2-1,331
Total Debt Repaid
-14,125-12,287-2,485-981.2-27,698
Net Debt Issued (Repaid)
-6,92714,93913,14723,651-26,871
Repurchase of Common Stock
--9,302---
Common Dividends Paid
-2,324-10.4-2,636-4,395-2,637
Other Financing Activities
-3,441-4,428-2,507-1,112-185
Financing Cash Flow
-12,6921,1988,00418,144-29,693

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
8,28891141.7-0.62
Miscellaneous Cash Flow Adjustments
1.86.6-64.1-32.5
Net Cash Flow
16,27621,784-10,0682,298-11,674

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
28,40619,568-3,458-170.529,636
Free Cash Flow Growth
45.17%---56.71%
Free Cash Flow Margin
8.44%6.17%-1.19%-0.07%12.63%
Free Cash Flow Per Share
48.9133.57-5.90-0.2950.58
Levered Free Cash Flow
13,18511,519-12,590-4,80312,129
Unlevered Free Cash Flow
15,58514,271-10,914-3,99712,359

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
3,4414,2032,5071,112185
Cash Income Tax Paid
18,32017,31417,6667,17212,582
Change in Working Capital
1,639-12,445-16,751-10,95015,578